BioSpace News Archive

AXP has taken a months’ long process riddled with pain points to a matter of days, while improving data quality and security to meet compliance and audit requirements.

This is the finding of a study published online in the April 11 edition of the New England Journal of Medicine.

True Ventures leads funding, pursues mission to invest in companies of broad and lasting impact

Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand female contraceptive

Candida auris deemed urgent threat by Centers for Disease Control and Prevention

Researchers have measured an optical clock’s ticking with record-breaking accuracy while also showing the clock can be operated with unprecedented consistency.

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Georgia C. Ravitz and James “Jamie” R. Ravitz have joined the firm’s life sciences practice as partners in the Washington, D.C., office

Takara Bio USA, Inc. announced today that its parent company, Takara Bio Inc., submitted a Drug Master File to the Food and Drug Administration for the liquid formulation of RetroNectin GMP grade on March 15, 2019

CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, along with POLL Medical, are excited to announce U.S. Food and Drug Administration (FDA) 510(k) clearance to market GrayDuck Stents™.